Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 71Carcinoma, Hepatocellular 26Prostatic Neoplasms 22Neoplasm Metastasis 19Neoplasms 18Carcinoma, Non-Small-Cell Lung 16Kidney Neoplasms 14Osteosarcoma 9Neuroendocrine Tumors 9Colorectal Neoplasms 9Carcinoma, Transitional Cell 9Carcinoma, Medullary 9Sarcoma 8Urinary Bladder Neoplasms 7Sarcoma, Ewing 7Melanoma 7Breast Neoplasms 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Recurrence 5Pancreatic Neoplasms 5Lung Neoplasms 5Carcinoma 5Urethral Neoplasms 4Triple Negative Breast Neoplasms 4Multiple Myeloma 4Liver Neoplasms 4Thyroid Cancer, Papillary 3

Interventions

Cisplatin 57Radiotherapy 35Radiotherapy, Intensity-Modulated 30Magnetic Resonance Spectroscopy 24Radiation 21Carboplatin 19pembrolizumab 18Specimen Handling 16Platinum 14Cetuximab 141,2-diaminocyclohexaneplatinum II citrate 14Surveys and Questionnaires 13Paclitaxel 13Biopsy 11Surgical Procedures, Operative 10Fluorouracil 10Docetaxel 9Taxes 8Nivolumab 8Drug Therapy 8Chemoradiotherapy 8durvalumab 7Fluorodeoxyglucose F18 7Observation 6Blood Specimen Collection 6fludarabine 5X-Rays 5Immunohistochemistry 5Cyclophosphamide 5aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × cabozantinib × Clear all
NCT05136196 2026-06-03

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

National Cancer Institute (NCI)

Phase 2 Recruiting
150 enrolled
DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡